ArticleBMC endocrine disorders2021
The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.
Article in BMC endocrine disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Early Transient Hypothyroidism Is Associated With Long-Term Outcomes of 131I Treatment in Graves' Disease: A Retrospective Cohort Study.Clinical endocrinology · 2026Article
- Graves' Disease Diagnosed during an Evaluation of an Abnormal Opacity on a Chest X-ray with a Review of the Pertinent Literature.Internal medicine (Tokyo, Japan) · 2026Review
- Papillary thyroid carcinoma in graves' disease: prevalence, clinicopathological features, and preoperative predictors.BMC surgery · 2026Article
- Low risk of thyroid eye disease (TED) following radioiodine (RAI) therapy in a multidisciplinary setting: a retrospective cohort study.Thyroid research · 2025Article
- K-Means Clustering Reveals Long-Term Thyrotropin Receptor Antibody Patterns in Graves' Disease: Insights from a 10-Year Study with Implications for Graves' Orbitopathy.Journal of clinical medicine · 2025Article
- Predictive Performance of 2 Immunoassays in Patients with Graves Disease Undergoing Radioiodine Therapy: Prospective Study.Journal of the Endocrine Society · 2025Article
- Effects of metabolic and organ function factors on the efficacy of radioactive iodine therapy for hyperthyroidism.Frontiers in endocrinology · 2025Article
- Impact of serum TRAb level changes on the efficacy ofFrontiers in endocrinology · 2025Article
- Coexistence of Hashimoto's Thyroiditis in Differentiated Thyroid Cancer: Post-Operative Monitoring of Anti-Thyroglobulin Antibodies and Assessment of Treatment Response.Diagnostics (Basel, Switzerland) · 2024Article
- A Review of Testing for Distinguishing Hashimoto's Thyroiditis in the Hyperthyroid Stage and Grave's Disease.International journal of general medicine · 2023Review
- Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves' disease.BMC endocrine disorders · 2022Article
- [Value of thyroidNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundGraves' disease (GD) is one of the most common autoimmune thyroid diseases (AITDs) in humans, and thyrotropin receptor antibody (TRAb) is a characterized autoantibody in GD. The use of radioactive iodine therapy (RAI) for GD treatment is increasing.
objectivesWe studied the biological properties of TRAb and evaluated the effect of RAI therapy on TRAb in GD patients.
methodsIn total, 225 patients (22 onset GD patients without
resultsSerum TRAb and thyroid peroxidase antibody (TPOAb) levels increased in the initial year of RAI treatment, and both antibodies decreased gradually after one year. After 5 years from radioiodine treatment, TRAb and TPOAb levels decreased in 88% and 65% of GD patients, respectively. The proportion of patients positive for thyroid-stimulatory antibody (TSAb) was significantly higher in the 7-12-month group, and thyroid-blocking antibody (TBAb) levels were elevated after one year in half of the patients who received
conclusionsTreatment of GD patients with radioiodine increased TPOAb and TRAb (their main biological properties were TSAbs) within the first year after therapy, and the main biological properties of elevated TRAb were TBAbs after 1 year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.